Skip to main content
BCDA logo

BCDA · BioCardia, Inc. · Earnings Call Transcripts & Audio

Track BCDA — free
$1.09 -0.02 (-1.80%)
Market Cap
$16.43M
Shares
15.14M

BioCardia, Inc. Earnings Call Transcripts

Quarterly earnings calls for BioCardia, Inc. (BCDA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-12
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
Confident tone Japan PMDA regulatory progress for CardiAMP FDA confirmatory trial pathway for CardiAMP-HF2 Helix Transcendocardial Delivery Catheter de novo pathway
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Confident tone Japan PMDA regulatory pathway Market opportunity and reimbursement Helix Transendocardial Delivery System
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
Confident tone Partnership and business development CardiAMP HF Phase III results Regulatory pathway and FDA/PMDA engagement
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
Positive tone Japan PMDA regulatory progress FDA regulatory engagement Helix transendocardial delivery system
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
Positive tone Japan PMDA Submission and Partnership Opportunity CardiAMP Heart Failure Trial Results and Regulatory Pathway Business Development and Partnering
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript
Positive tone Tariffs and Most Favored Nation Pricing Business Development and Partnerships Morph DNA Steerable Introducer Platform
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
Confident tone Japan Regulatory Pathway (PMDA) CardiAMP Heart Failure I Trial Readout CardiAMP Heart Failure II Trial Enrollment
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
Positive tone CardiALLO Allogeneic Cell Therapy CardiAMP Heart Failure I Trial Business Development and Partnerships
Revenue
$3,000
▼ 93% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
Confident tone Japan PMDA Regulatory Pathway CardiAMP Heart Failure Trial Results Japanese Commercialization Strategy
Revenue
$55,000
▼ 14.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
Positive tone Unmet Need in Heart Failure Clinical Trial Execution and Enrollment CardiAMP Heart Failure Trial (BCDA-01) Results
Revenue
$13,000*
▼ 87.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
Revenue
$357,000
▲ 68.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript
Revenue
$43,000
▼ 95.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript
Revenue
$64,000
▲ 6.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
Revenue
$106,000*
▲ 34.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
Revenue
$212,000
▼ 74.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
BioCardia, Inc. (BCDA) Q2 2022 Earnings Call Transcript
Revenue
$974,000
▲ 1311.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
BioCardia, Inc. (BCDA) Q1 2022 Earnings Call Transcript
Revenue
$60,000
▲ 30.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
BioCardia, Inc. (BCDA) Q4 2021 Earnings Call Transcript
Revenue
$79,000*
▲ 71.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q1
2021-05-13
BioCardia, Inc. (BCDA) Q1 2021 Earnings Call
Revenue
$46,000
▲ 21.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
BioCardia, Inc. (BCDA) Q4 2020 Earnings Call
Revenue
$46,000*
▼ 78.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-13
BioCardia, Inc. (BCDA) Q2 2020 Earnings Call
Revenue
$27,000
▼ 68.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts CIK 925741 CUSIP 09060U606 13F (30d) 13 filings 13 filers Visit website Investor relations